Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (29)
Kadja Luana Chagas Monteiro, Marcone Gomes dos Santos Alcântara, Nathalia Monteiro Lins Freire, Thiago Mendonça de Aquino & Edeildo Ferreira da Silva-Júnior. 2023. Antibiotics - Therapeutic Spectrum and Limitations. Antibiotics - Therapeutic Spectrum and Limitations
437
478
.
Thomas Sécher, Emilie Dalonneau, Marion Ferreira, Christelle Parent, Nicolas Azzopardi, Gilles Paintaud, Mustapha Si-Tahar & Nathalie Heuzé-Vourc'h. (2019) In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration. Journal of Controlled Release 303, pages 24-33.
Crossref
Crossref
Olufunmiso Olajuyigbe, Morenike Adeoye-Isijola, Babasola Osopale & Roger Coopoosamy. (2018) In vitro Effects of Magnesium-Aluminum Hydroxide (Maalox) on the Antibacterial Activity of Ciprofloxacin against Clinical Bacterial Isolates. Journal of Pure and Applied Microbiology 12:2, pages 623-632.
Crossref
Crossref
Aryan J. RahbarThomas P. LodisePrasad AbrahamAlissa LockwoodManjunath P. PaiJohn PatkaMarina RabinovichKaren CurzioKatleen ChesterBrian WilliamsBryan MorseMitchell ChaarVanthida HuangJeffrey Salomone. (2016) Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis. Surgical Infections 17:6, pages 675-682.
Crossref
Crossref
Qin Wang, Huayin Li, Jian Zhou, Ming Zhong, Duming Zhu, Nana Feng, Fanglei Liu, Chunxue Bai & Yuanlin Song. (2014) PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury. Respiratory Physiology & Neurobiology 193, pages 21-28.
Crossref
Crossref
Brian J. Morrow, Christopher M. Pillar, Jennifer Deane, Daniel F. Sahm, A. Simon Lynch, Robert K. Flamm, Janet Peterson & Todd A. Davies. (2013) Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagnostic Microbiology and Infectious Disease 75:4, pages 412-416.
Crossref
Crossref
T. Secher, L. Fauconnier, A. Szade, O. Rutschi, S. C. Fas, B. Ryffel & M. P. Rudolf. (2011) Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection. Journal of Antimicrobial Chemotherapy 66:5, pages 1100-1109.
Crossref
Crossref
Geraldine S. Hall & Gail L. Woods. 2011. Henry's Clinical Diagnosis and Management by Laboratory Methods. Henry's Clinical Diagnosis and Management by Laboratory Methods
1079
1115
.
Keith S. Kaye, Paul Auwaerter, John A. Bosso, Nathan C. Dean, Gary V. Doern, Michael B. Kays, Jason M. Pogue, David J. Ritchie & Brian Wispelwey. (2010) Strategies to Address Appropriate Fluoroquinolone Use in the Hospital. Hospital Pharmacy 45:11, pages 844-853.
Crossref
Crossref
Amy Arnold, Sara D. Brouse, William D. Pitcher & Ronald G. HallIIII. (2010) Empiric Therapy for Gram-Negative Pathogens in Nosocomial and Health Care-Associated Pneumonia: Starting With the End in Mind. Journal of Intensive Care Medicine 25:5, pages 259-270.
Crossref
Crossref
Luke F. Chen & Donald Kaye. (2009) Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides. Infectious Disease Clinics of North America 23:4, pages 1053-1075.
Crossref
Crossref
M. Montero, M. Domínguez, M. Orozco-Levi, M. Salvadó & H. Knobel. (2008) Mortality of COPD Patients Infected with Multi-Resistant Pseudomonas aeruginosa: A Case and Control Study. Infection 37:1, pages 16-19.
Crossref
Crossref
Philip Toltzis & Jeffrey L. Blumer. 2009. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. Feigin and Cherry's Textbook of Pediatric Infectious Diseases
3132
3156
.
David K. Henderson. 2009. Antimicrobial Drug Resistance. Antimicrobial Drug Resistance
1295
1314
.
Marin H. Kollef, Lena M. Napolitano, Joseph S. Solomkin, Richard G. Wunderink, In‐Gyu Bae, Vance G. Fowler, Robert A. Balk, Dennis L. Stevens, James J. Rahal, Andrew F. Shorr, Peter K. Linden & Scott T. Micek. (2008) Health Care–Associated Infection (HAI): A Critical Appraisal of the Emerging Threat—Proceedings of the HAI Summit. Clinical Infectious Diseases 47:s2, pages S55-S99.
Crossref
Crossref
H. Ben Abdallah, S. Noomen, A. Ben Elhadj Khélifa, O. Sahnoun, A. Elargoubi & M. Mastouri. (2008) Profil de sensibilité aux antibiotiques des souches de Pseudomonas aeruginosa isolées dans la région de Monastir. Médecine et Maladies Infectieuses 38:10, pages 554-556.
Crossref
Crossref
Majdi N. Al-Hasan, John W. Wilson, Brian D. Lahr, Jeanette E. Eckel-Passow & Larry M. Baddour. (2008) Incidence of Pseudomonas aeruginosa Bacteremia: A Population-Based Study. The American Journal of Medicine 121:8, pages 702-708.
Crossref
Crossref
A.P. Fonseca & J.C. Sousa. (2007) Effect of antibiotic-induced morphological changes on surface properties, motility and adhesion of nosocomial Pseudomonas aeruginosa strains under different physiological states. Journal of Applied Microbiology 103:5, pages 1828-1837.
Crossref
Crossref
A.P. Fonseca & J.C. Sousa. (2007) Effect of shear stress on growth, adhesion and biofilm formation of Pseudomonas aeruginosa with antibiotic-induced morphological changes. International Journal of Antimicrobial Agents 30:3, pages 236-241.
Crossref
Crossref
Jaffar A. Al-Tawfiq. (2007) Occurrence and antimicrobial resistance pattern of inpatient and outpatient isolates of Pseudomonas aeruginosa in a Saudi Arabian hospital: 1998–2003. International Journal of Infectious Diseases 11:2, pages 109-114.
Crossref
Crossref
Thomas P. Lodise, Christopher D. Miller, Jeffrey Graves, Jon P. Furuno, Jessina C. McGregor, Ben Lomaestro, Eileen Graffunder & Louise-Anne McNutt. (2007)
Clinical Prediction Tool To Identify Patients with
Pseudomonas aeruginosa
Respiratory Tract Infections at Greatest Risk for Multidrug Resistance
. Antimicrobial Agents and Chemotherapy 51:2, pages 417-422.
Crossref
Crossref
Aysen Bayram & Iclal Balci. (2006) Patterns of antimicrobial resistance in a surgical intensive care unit of a university hospital in Turkey. BMC Infectious Diseases 6:1.
Crossref
Crossref
Burke A. Cunha. (2006) New Uses for Older Antibiotics: Nitrofurantoin, Amikacin, Colistin, Polymyxin B, Doxycycline, and Minocycline Revisited. Medical Clinics of North America 90:6, pages 1089-1107.
Crossref
Crossref
Keith S. Kaye, Zeina A. Kanafani, Ashley E. Dodds, John J. Engemann, Stephen G. Weber & Yehuda Carmeli. (2006)
Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant
Pseudomonas aeruginosa
. Antimicrobial Agents and Chemotherapy 50:6, pages 2192-2196.
Crossref
Crossref
E. Kipnis, T. Sawa & J. Wiener-Kronish. (2006) Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Médecine et Maladies Infectieuses 36:2, pages 78-91.
Crossref
Crossref
Mark W. Garrison. (2006) Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease 54:1, pages 51-56.
Crossref
Crossref
Simona Roveta, Anna Maria Schito, Anna Marchese & Gian Carlo Schito. (2005) Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. International Journal of Antimicrobial Agents 26:5, pages 366-372.
Crossref
Crossref
Dana Maglio,Joseph L. Kuti,David P. Nicolau,. (2005) Simulation of Antibiotic Pharmacodynamic Exposure for the Empiric Treatment of Nosocomial Bloodstream Infections: A Report from the OPTAMA Program. Clinical Therapeutics 27:7, pages 1032-1042.
Crossref
Crossref
F. Van Bambeke, J.-M. Michot, J. Van Eldere & P.M. Tulkens. (2005) Quinolones in 2005: an update. Clinical Microbiology and Infection 11:4, pages 256-280.
Crossref
Crossref